Comment on Media Report
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
HAMBURG，德國 / ACCESSWIRE / 2024年11月14日 / Evotec SE（法蘭克福證券交易所：EVT）（SDAX/TecDAX，主板，ISIN：DE 000 566480 9，WKN 566480（納斯達克：EVO）關於媒體報道，Evotec SE（"公司"）宣佈收到了列在美國的生物技術公司Halozyme Therapeutics Inc.的非約束性意向表達，內容涉及向公司股東發出的收購要約，每股價格爲11.00歐元。公司將認真分析這一意向表達，決定下一步措施，並根據法律要求通知資本市場。
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com
聯繫人：沃爾克·布勞恩，全球投資者關係及esg負責人，Evotec SE，曼弗雷德·艾根校園，埃塞納博根7號，22419漢堡，德國，電話：+49 (0) 151 1940 5058（手機），volker.braun@evotec.com
SOURCE: Evotec SE
來源：Evotec SE
譯文內容由第三人軟體翻譯。
